Overview: Parvovirus B19 Qualitative PCR TestIntroduction: The Parvovirus B19 Qualitative PCR Test detects Parvovirus B19 DNA to diagnose active infection, causing anemia or rash. Following 2023 IDSA guidelines, it uses PCR for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in virology for patients with suspected active parvovirus B19 infection, particularly in pregnant women or immunocompromised individuals.
Other Names: Parvovirus PCR Assay, B19 DNA Detection Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: Parvovirus B19 PCR testing began in the 1990s with viral DNA research. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects Parvovirus B19 DNA to diagnose active infection, guides treatment, and evaluates patients with anemia or rash.
Test Parameters: 1. Parvovirus B19 DNA
Pretest Condition: No fasting required. Collect whole blood, serum, plasma, CSF, or saliva. Report history of anemia, rash, or parvovirus exposure.
Specimen: Whole Blood (EDTA, 2-5 mL), Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL), CSF (sterile container, 1-2 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document anemia, rash, or history of parvovirus exposure. Include current medications, especially in pregnancy or immunosuppression.
Consent: Written consent required, detailing the tests purpose, parvovirus infection implications, and risks of sample collection.
Procedural Considerations: Uses qualitative PCR to detect Parvovirus B19 DNA. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for active parvovirus infection diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Positive DNA confirms active infection, guiding monitoring or supportive care. Negative results may require serology testing.
Specialist Consultation: Consult an infectious disease specialist or obstetrician for result interpretation and treatment planning.
Additional Supporting Tests: Parvovirus B19 IgM/IgG, fetal ultrasound, or CBC to confirm active parvovirus infection.
Test Limitations: Not all active infections have detectable DNA; clinical correlation is needed. Sample quality affects sensitivity.
References: IDSA Parvovirus Guidelines, 2023; Clinical Infectious Diseases, Brown KE, 2022.
